Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Rocket Pharmaceuticals (RCKT) Surges on Encouraging Study Data

by Zacks Equity Research

Rocket Pharmaceuticals' (RCKT) AAV-based gene therapy candidate demonstrates early evidence of clinical benefit and tolerability in patients with Danon disease, which affects the cardiac muscle.

Roche (RHHBY), Moderna Ink Deal for Coronavirus Antibody Test

by Zacks Equity Research

Roche (RHHBY) partners with Moderna to allow the latter utilize its Elecsys Anti-SARS-CoV-2 S antibody test in the mRNA-1273 vaccine research studies.

Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates

by Zacks Equity Research

Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma. Stock up 350%.

Sarepta (SRPT) DMD Study Shows Proof of Concept for SRP-5051

by Zacks Equity Research

Sarepta's (SRPT) ongoing phase II study data supports continued dose escalation of SRP-5051 and suggests improved efficacy on lower doses compared to Exondys 51.

Kinjel Shah headshot

Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates

by Kinjel Shah

Pfizer (PFE) COVID-19 vaccine gets approval for emergency use in the United Kingdom while Roche's (RHHBY) Xolair gets FDA nod for new indication.

AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier

by Zacks Equity Research

AbbVie (ABBV) signs a global deal with Frontier Medicines to make innovative therapies and E3 degraders against difficult-to-drug targets.

Roche's (RHHBY) Xolair Gets FDA Nod for Label Expansion

by Zacks Equity Research

Roche (RHHBY) wins FDA approval of the label expansion of Xolair along with EUA for a serology test.

Blueprint Medicines' (BPMC) Gavreto Approved for Thyroid Cancer

by Zacks Equity Research

The FDA grants accelerated nod to Blueprint Medicines' (BPMC) Gavreto for treating patients with advanced/metastatic RET-altered thyroid cancer.

Kinjel Shah headshot

Pharma Stock Roundup: AZN COVID-19 Vaccine Interim Data, PFE Emergency Use Appeal

by Kinjel Shah

AstraZeneca (AZN) COVID-19 vaccine candidate proves effective in late-stage study. Pfizer (PFE) seeks Emergency use for its COVID-19 vaccine candidate.

Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer

by Zacks Equity Research

Bristol Myers (BMY) obtains EC approval for Opdivo as a second-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

Roche (RHHBY) Gets FDA Nod for Influenza Drug Label Expansion

by Zacks Equity Research

Roche (RHHBY) gets FDA approval for Xofluza to prevent influenza in people 12 years of age and older following contact with someone with influenza.

Roche's (RHHBY) Influenza Drug Gets Positive CHMP Opinion

by Zacks Equity Research

Roche's (RHHBY) influenza drug Xofluza and Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) get a positive CHMP opinion.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Coronavirus Data, FDA Emergency Tag for LLY COVID-19 Drug

by Kinjel Shah

Eli Lilly (LLY) and Pfizer (PFE) provide updates on their coronavirus vaccine/antibody candidates.

Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut

by Zacks Equity Research

Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.

ImmunoGen (IMGN) Q3 Earnings & Sales Top, Pipeline on Track

by Zacks Equity Research

ImmunoGen (IMGN) reports encouraging third-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.

Biogen Alzheimer's Drug Aducanumab Gets Rejected by FDA Panel

by Zacks Equity Research

If Biogen's (BIIB) aducanumab is approved by the FDA going forward, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

TEVA Posts In-Line Q3 Earnings, Lowers Sales View, Stock Down

by Zacks Equity Research

TEVA's earnings match estimates while sales miss the same for third-quarter 2020. It lowers its previously issued sales guidance for 2020. Stock down.

Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Exelixis (EXEL) posts a wider-than-expected loss for the third quarter but beats on revenues.

Prothena (PRTA) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Prothena (PRTA) misses earnings and sales estimates in the third quarter of 2020.

Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises

by Zacks Equity Research

Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.

Seagens (SGEN) Q3 Earnings Rise Y/Y, Adcetris Sales View Cut

by Zacks Equity Research

Seagen's (SGEN) bottom line grows year over year in Q3 while revenues beat estimates. The company lowers the sales guidance for its lead product Adcetris.

AbbVie (ABBV) Beats on Q3 Earnings & Sales, Ups 2020 Guidance

by Zacks Equity Research

AbbVie (ABBV) beats on third-quarter 2020 earnings and revenues. Shares up in pre-market trading.

Amgen (AMGN) Q3 Earnings Top, Prolia, Biosimilars Drive Sales

by Zacks Equity Research

Amgen (AMGN) beats Q3 estimates for both earnings and sales. It slightly narrows its previously issued sales guidance for 2020 while raising its earnings range.

Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Blueprint Medicines' (BPMC) both bottom and the top line trump estimates in Q3. Ayvakit's sales rise sequentially.

Sheraz Mian headshot

Top Research Reports for UnitedHealth, Adobe & Pfizer

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Adobe (ADBE) and Pfizer (PFE).